RecruitingNot ApplicableNCT02880163

REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam

Reducing Exsanguination Via In-Vivo Expandable Foam

Sponsor

Arsenal Medical, Inc.

Enrollment

40 participants

Start Date

Aug 7, 2025

Study Type

INTERVENTIONAL

Conditions

Trauma Hemorrhagic Shock Exsanguinating Hemorrhage Shock; Traumatic

Summary

The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.

Eligibility

Min Age: 15 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called ResQFoam for people with exsanguinating hemorrhage, hemorrhagic shock, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 15 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.